|Day Low/High||12.78 / 13.19|
|52 Wk Low/High||12.56 / 88.54|
The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.
The investigation is in relation to drug pricing in the pharmaceutical industry.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
Biogen's new spine disease drug outperformed expectations during its commercial debut.
Organovo, Endo and Omeros were among the biotech stock moves in premarket trading on Thursday.
Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.
Endo International slipped 5% ahead of market's open Friday.
An FDA advisory committee has found that risks of Endo International's pain drug Opana ER now overshadow the drug's benefits.
We answer recent reader questions about three of the biotech stocks we regularly cover.
Amicus Therapeutics, Nantkwest and Organovo are among the premarket biotech movers on Tuesday.
Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Endo International plc (NASDAQ:ENDP) securities...
The share prices of Mylan, Sears and Endo International fell dramatically in 2016, and the companies face significant challenges ahead.
If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.
There are more dogs on the S&P 500 than on the Dow. Here's one example.
Glancy Prongay & Murray LLP ("GPM") reminds investors of the January 6, 2017 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired...